CBIO
Crescent Biopharma Inc
NASDAQ · Biotechnology
$9.51
+0.10 (+1.06%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 57.99M | 51.60M | 54.22M |
| Net Income | 180.8K | 210.8K | 183.8K |
| EPS | — | — | — |
| Profit Margin | 0.3% | 0.4% | 0.3% |
| Rev Growth | +8.6% | +24.1% | +21.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 58.46M | 55.07M | 55.38M |
| Total Equity | 113.09M | 116.97M | 133.63M |
| D/E Ratio | 0.52 | 0.47 | 0.41 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 390.2K | 358.0K | 370.7K |
| Free Cash Flow | 84.1K | 101.4K | 117.1K |